Non-V600 BRAF mutations recurrently found in lung cancer predict sensitivity to the combination of Trametinib and Dabrafenib

Approximately half of BRAF-mutated Non-small cell lung cancers (NSCLCs) harbor a non-V600 BRAF mutation, accounting for ∼40,000 annual deaths worldwide. Recent studies have revealed the benefits of combined targeted therapy with a RAF-inhibitor (Dabrafenib) and a MEK-inhibitor (Trametinib) in treati...

Descripción completa

Detalles Bibliográficos
Autores principales: Noeparast, Amir, Teugels, Erik, Giron, Philippe, Verschelden, Gil, De Brakeleer, Sylvia, Decoster, Lore, De Grève, Jacques
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5601124/
https://www.ncbi.nlm.nih.gov/pubmed/28947956
http://dx.doi.org/10.18632/oncotarget.11635

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5601124/
https://www.ncbi.nlm.nih.gov/pubmed/28947956
http://dx.doi.org/10.18632/oncotarget.11635

Ejemplares similares